FCCC LOGO Faculty Publications
Visvanathan K , Chlebowski RT , Hurley P , Col NF , Ropka M , Collyar D , Morrow M , Runowicz C , Pritchard KI , Hagerty K , Arun B , Garber J , Vogel VG , Wade JL , Brown P , Cuzick J , Kramer BS , Lippman SM
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
Journal of Clinical Oncology. 2009 Jul;27(19) :3235-3258
PMCID: PMC 2716943   
Back to previous list
Purpose To update the 2002 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. Methods A literature search identified relevant randomized trials published since 2002. Primary outcome of interest was BC incidence (invasive and noninvasive). Secondary outcomes included BC mortality, adverse events, and net health benefits. An expert panel reviewed the literature and developed updated consensus guidelines. Results Seventeen articles met inclusion criteria. In premenopausal women, tamoxifen for 5 years reduces the risk of BC for at least 10 years, particularly estrogen receptor (ER)-positive invasive tumors. Women <= 50 years of age experience fewer serious side effects. Vascular and vasomotor events do not persist post-treatment across all ages. In postmenopausal women, raloxifene and tamoxifen reduce the risk of ER-positive invasive BC with equal efficacy. Raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in BC risk from either agent translates into reduced BC mortality. Recommendations In women at increased risk for BC, tamoxifen (20 mg/d for 5 years) may be offered to reduce the risk of invasive ER-positive BC, with benefits for at least 10 years. In postmenopausal women, raloxifene (60 mg/d for 5 years) may also be considered. Use of aromatase inhibitors, fenretinide, or other selective estrogen receptor modulators to lower BC risk is not recommended outside of a clinical trial. Discussion of risks and benefits of preventive agents by health providers is critical to patient decision making. J Clin Oncol 27: 3235-3258. (C) 2009 by American Society of Clinical Oncology
Visvanathan, Kala Chlebowski, Rowan T. Hurley, Patricia Col, Nananda F. Ropka, Mary Collyar, Deborah Morrow, Monica Runowicz, Carolyn Pritchard, Kathleen I. Hagerty, Karen Arun, Banu Garber, Judy Vogel, Victor G. Wade, James L. Brown, Powel Cuzick, Jack Kramer, Barnett S. Lippman, Scott M. AMER SOC CLINICAL ONCOLOGY 463TD